Supply Chain Intelligence

Kyverna Therapeutics, Inc. Supply Chain

KYTX supply chain intelligence for Kyverna Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

KYTX ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

12Suppliers
5Customers
2Debt Items
20Related Chains

Kyverna Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
OXFORD-BIOMEDICA-UK-LIMITED OXFORD-BIOMEDICA-UK-LIMITED 90% Pursuant to our license and supply agreement with Oxford Biomedica (UK) Limited, or Oxford, Oxford provides us with lentiviral vector process development servi
CABA Cabaletta Bio, Inc. 72% Reciprocal relationship from CABA graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from CABA graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from CABA g…
CABA Cabaletta Bio, Inc. 72% a have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (i) any breach of our respective representations, warranties and obligations t…
FATE Fate Therapeutics, Inc. 72% Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purpos…
GILD Gilead Sciences, Inc. 72% . The Company recognized $ million and in impairment charges related to capitalized software as research and development expenses in the statement of operations and comprehensive loss for the years e…
GILD Gilead Sciences, Inc. 72% Reciprocal relationship from GILD graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from GILD g…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from KYTX graph: a have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out …
JNJ Johnson & Johnson 72% a have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (i) any breach of our respective representations, warranties and obligations t…
NTLA Intellia Therapeutics, Inc. 72% Reciprocal relationship from NTLA graph: Reciprocal relationship from KYTX graph: certain regulatory-and clinical-related benchmarks are due to the NIH, with the minimum cumulative royalty due for a …
NTLA Intellia Therapeutics, Inc. 72% certain regulatory-and clinical-related benchmarks are due to the NIH, with the minimum cumulative royalty due for a product reaching FDA approval or foreign-equivalent approval totaling $ million fo…
RNAC Cartesian Therapeutics, Inc. 72% Reciprocal relationship from RNAC graph: Reciprocal relationship from KYTX graph: a have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out…
RNAC Cartesian Therapeutics, Inc. 72% a have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (i) any breach of our respective representations, warranties and obligations t…

Kyverna Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
FATE Fate Therapeutics, Inc. 72% Reciprocal relationship from FATE graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK m…
GILD Gilead Sciences, Inc. 72% ase 1 data from both of these trials in the second half of 2025. In November 2024, we presented clinical data at ACR Convergence 2024 that demonstrated positive sustained efficacy and durability at >…
GILD Gilead Sciences, Inc. 72% Reciprocal relationship from GILD graph: Reciprocal relationship from KYTX graph: ase 1 data from both of these trials in the second half of 2025. In November 2024, we presented clinical data at ACR …
NTLA Intellia Therapeutics, Inc. 72% certain regulatory-and clinical-related benchmarks are due to the NIH, with the minimum cumulative royalty due for a product reaching FDA approval or foreign-equivalent approval totaling $ million fo…
NTLA Intellia Therapeutics, Inc. 72% Reciprocal relationship from NTLA graph: Reciprocal relationship from KYTX graph: certain regulatory-and clinical-related benchmarks are due to the NIH, with the minimum cumulative royalty due for a …

Kyverna Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
KYTX-DEBT-10598 Xbrl Convertible 90% xbrl convertible detail from xbrl 2024-12-31.
KYTX-DEBT Debt stack $33.8M 90% Market cache reports total debt of $33.8M.

Kyverna Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Kyverna Therapeutics, Inc..

Kyverna Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
KYTX-OWNER-GORDONMD-GLOBAL-INVESTMENTS-LP GordonMD Global Investments LP 90% 13F overlay lists GordonMD Global Investments LP as top holder; 113 tracked holders.

Kyverna Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CELU Celularity Inc. 100.00 2
GDTC CytoMed Therapeutics Limited 100.00 2
CLLS Cellectis S.A. 100.00 2
VEEV Veeva Systems Inc. 100.00 2
CRBU Caribou Biosciences, Inc. 100.00 2
DTIL Precision BioSciences, Inc. 100.00 2
AUTL Autolus Therapeutics plc 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
CRIS Curis, Inc. 100.00 2
AVIR Atea Pharmaceuticals, Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
VERA Vera Therapeutics, Inc. 100.00 2
CGEM Cullinan Therapeutics, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
ALMS Alumis Inc. 100.00 2
CABA Cabaletta Bio, Inc. 100.00 2 ['supplier']
CAH Cardinal Health, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
IBIO iBio, Inc. 100.00 2
View KYTX supply chain intel →

Explore the full interactive supply chain map for Kyverna Therapeutics, Inc..

Open KYTX supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map